ALNYLAM PHARMACEUTICALS, INC.

Lobbying for ALNYLAM PHARMACEUTICALS, INC. · Pharmaceutical manufacturer

Filing 3rd Quarter - Report

3rd Quarter (July 1 - Sep 30) 2025 · Massachusetts · House · Senate · $390,000.00 expenses · posted Oct 20, 2025

Bills named in this filing 1

Lobbying activity 3

Medicare/Medicaid

Issues related to the implementation of the Inflation Reduction Act; HR.4993, Joe Fiandra Access to Home Infusion Act

Trade (domestic/foreign)

Issues relating to supply chain tariffs

Pharmacy

Implementation of The Creating and Restoring Equal Access to Equivalent Samples (CREATES) Act (PL 116-94)

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.